biomedicines

IMPACT FACTOR 4.7

Indexed in: PubMed

CITESCORE 3.7

an Open Access Journal by MDPI

Sickle Cell Disease: Recent Advances in Pathophysiology and Therapy

Guest Editor:

Dr. Tomasz Brzóska
Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, Division of Hematology/Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA

Deadline for manuscript submissions:
closed (31 August 2023)

Message from the Guest Editor

It has been more than a century since James Herrick, a Professor of Medicine in Chicago, for the first time, described abnormally sickle-shaped erythrocytes in a blood smear from a student of Caribbean ancestry. Since then, our understanding of sickle cell disease (SCD) improved immensely. Over the past decade in particular, major global efforts have been mounted to address the convergence of multiple pathological phenomena, such as hemoglobin S polymerization–dependent erythrocyte hemolysis and sickling, vasoocclusion-dependent ischemia-reperfusion injury, endothelial dysfunction–dependent vasculopathy, and sterile inflammation, to promote multi-organ acute and chronic complications in SCD. These studies inspired the development of several therapies that are either already approved or currently in clinical trials.

I invite papers on the following topics:

- Acute and chronic organ complications in SCD: pathophysiology, current and future therapies;
- Sterile inflammation in SCD: pathophysiology, current and future therapies;
- Emerging role of extracellular vesicles in the pathophysiology, diagnosis and treatment of SCD.

biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI